27
Apr
Glenmark Pharmaceuticals Limited is concluding the final phase of its marketing approval application process to enable launch of its innovative nasal spray in 17 countries in the European Union. Ryaltris will shortly be available in Austria, Belgium, Czech Republic, Germany, Denmark, Spain, Finland, France, Ireland, Italy, The Netherlands, Norway, Poland, Romania, Slovakia, Sweden, and the UK. Glenmark will commercialise Ryaltris on its own in select markets. In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark. Ryaltris, developed by Glenmark, is…